The National Comprehensive Cancer Network has updated their guidelines for the treatment of ovarian cancer, including therapy for stage II-IV disease and persistent disease.
Research presented at the 2018 BMT Tandem Meetings showed that potential role of immune checkpoint inhibitors in the post-transplant setting for patients with relapsed or large B-cell lymphomas.
Clinical pathways may require a deeper consideration of the patient experience in order to achieve the goals of the Triple Aim, according to Winston Wong, PharmD.
CAR T-cell therapy may compliment HSCT for improving survival in ALL without increasing the risk of severe graft-versus-host disease, according to research presented at the 2018 BMT Tandem Meetings.
A recent study compared the effects of a collaborative care intervention vs usual care on health status of patients with chronic heart failure.
The NCCN has selected Envision's medical affairs platform to help manage proposals and investigator-initiated clinical trials in an effort to improve patient quality of life and reduce cancer-related deaths.
The National Comprehensive Cancer Network has released the first-ever clinical practice guidelines addressing patients living with HIV who are diagnosed with cancer to help them receive safe and necessary treatment.
The US Food and Drug Administration has granted approval to a therapy in combination with an aromatase inhibitor for the treatment of a specific type of advanced breast cancer.
Women with breast cancer are often afraid of getting radiation, but a new study of women who’ve had this treatment suggests their experiences with it were much better than they expected.
The National Comprehensive Cancer Network issued updated guidelines for prostate cancer, including new information about the role of family history, specific mutations, and microsatellite instability testing.